Join our Live Stream
The Value of Point-of-Care Testing in
Diabetes and Comorbidities Management in the Context of
30th November | 15:30 — 17:00 CET
CPD and CME Accredited
Professor Oliver Schnell
Welcome and introductions
Prof. Bernd Schultes
Insights from a Swiss competence centre for diabetology
Dr Devaki Nair
COVID-19 and diabetes in the UK – screening and monitoring
Dr Peter Johansson
Implementing a one stop shop for diabetes check-ups in a health care setting in Sweden
Dr Enrico Torre
Perspective from Italy on Diabetes patients testing before and during the COVID-19 pandemic
Prof. Neale Cohen
Alternative ways to manage diabetes patients during COVID-19. The point of care testing drive through experience
Dr Erna Lenters-Westra
Can high accuracy be achieved with point-of-care testing?
Join our panel of experts from around the world for this compelling event presenting a view from the front line on the management of diabetes patients and comorbidities in the context of COVID-19.
With telehealth and remote treatment on the rise, a unique and international group of experts will analyse how rapid point-of-care testing may benefit patients with diabetes in the COVID-19 healthcare landscape and beyond.
Screening and monitoring of diabetes and cardiovascular patients is even more critical nowadays. According to the World Health Organisation, individuals may be more susceptible to severe COVID-19 and death if they have a noncommunicable disease, such as diabetes, high blood pressure, cardiac disease, kidney disease, chronic lung disease, cerebrovascular disease or cancer. Diabetes has not yet been shown to increase the likelihood of SARS-CoV-2 infection, but progression to severe illness is more likely in people with diabetes.2 The frequency of diabetes among COVID-19 patients requiring hospitalisation or intensive care is two to three times higher than in the overall population, and mortality rates in those with diabetes are also higher.       .
In this educational event, the group of experts will share new strategies for the management of diabetes and comorbidities and how countries around the world are successfully adopting rapid HbA1c and lipid pointof-care testing for the continued remote management of diabetes and cardiovascular patients during COVID-19 and beyond.
Professional Blended Learning Continuum
- MyPOCAcademy is an interactive educational resource providing information on the rationale for Point of Care Testing testing and its value, across a number of medical specialities.
- The courses will allow you to enhance your knowledge and skills at your own pace.
- CME-accredited materials and webinars will be available shortly
Assess Your Understanding
- Within each course are test questions that allow you to test your knowledge.
- Interactive patient case studies enable you to view the benefits of Point of Care Testing in real-life clinical scenarios
Convenient Access to Latest POC Information
- MyPOCAcademy is your go-to resource for the latest information related to Point of Care Testing.
- Learning can be accessed at your convenience with the click of a button.
- ↑ World Health Organisation. Clinical management of COVID-19: Interim guidance, 27 May 2020. WHO/2019-nCoV/clinical/2020.5. —
- ↑ Riddle M, Buse JB, Franks PW, et al. COVID-19 in People With Diabetes: Urgently needed Lessons From Early Reports. Diabetes Care. Published online May 14, 2020. —
- ↑ Centers for Disease Control and Prevention. COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. Morbidity and Mortality Weekly Report. April 3, 2020;69(13):382-386. — https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
- ↑ Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalised With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059. —
- ↑ Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalised in the United States. J Diabetes Sci Technol. Published online May 9, 2020. —
- ↑ Palmieri L, Andrianou X, Barbariol P, et al. COVID-19 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on April 20, 2020. EpiCentro. Accessed June 5, 2020. — https://www.epicentro.iss.it/en/coronavirus/ bollettino/Report-COVID-2019_20_April_2020.pdf
- ↑ Chen Y, Yang D, Cheng B. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose Lowering Medication. Diabetes Care. Published online May 14, 2020. —
- ↑ Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020;382:1708-20. —
- ↑ Lian J, Liang Y. Curr Med Res & Op. 2014;30(11):2233-2240. —
- ↑ Egbunike V, Gerard S. Diabetes Educator. 2013;39(1):66-73. —
- ↑ Lee-Lewandrowski L, Yeh S, Baron J, Crocker JB, Lewandrowski K. Clin Chim Acta. 2017;473:71-74. —
- ↑ Crocker JB, Lee-Lewandrowski E, Lewandrowski N, Baron J, Gregory K, Lewandrowski K. AJCP. 2014;142:640-646 —